Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market ...

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...
Healio

Alternative complement pathway inhibition may be key to lupus management

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
WDAF-TV

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway ...

RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated >99 percent ...
MedCity News

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.